Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

(2017) Kevin Fitzgerald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials

(2016) Paul M. Ridker et al.   AMERICAN HEART JOURNAL

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials

(2016) Peter H. Jones et al.   AMERICAN JOURNAL OF CARDIOLOGY

PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study

(2016) Jin M. Cheng et al.   ATHEROSCLEROSIS

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE

(2016) Karin Leander et al.   CIRCULATION

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective

(2016) Gissette Reyes-Soffer et al.   CIRCULATION

PCSK9 Association With Lipoprotein(a)Novelty and Significance

(2016) Hagai Tavori et al.   CIRCULATION RESEARCH

Statins and Their Effect on PCSK9—Impact and Clinical Relevance

(2016) Beth A. Taylor et al.   Current Atherosclerosis Reports

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

(2016) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis

(2016) Anne Langsted et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

(2016) Brian A. Ference et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance

(2015) Ji Miao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

(2015) Xin-Lin Zhang et al.   BMC Medicine

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

(2015) Michael J. Lipinski et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

(2015) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention

(2015) Kenichi Tsujita et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Low prognostic utility of measuring PCSK9 levels in ACS

(2015) Gregory B. Lim   Nature Reviews Cardiology

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9

(2014) Evan A. Stein et al.   Annual Review of Medicine

Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

(2014) Jennifer G. Robinson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies

(2014) Naif A. M. Almontashiri et al.   PLoS One

Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia

(2013) Michael J. Koren et al.   CIRCULATION

Low Prevalence of Mutations in Known Loci for Autosomal Dominant Hypercholesterolemia in a Multiethnic Patient Cohort

(2012) Zahid Ahmad et al.   Circulation-Cardiovascular Genetics

Loss- and Gain-of-function PCSK9 Variants

(2012) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

(2012) James M. McKenney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

(2012) Evan A. Stein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein

(2011) Fen Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of Two Intensive Statin Regimens on Progression of Coronary Disease

(2011) Stephen J. Nicholls et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans

(2010) Lena Persson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

(2010) Jeffrey D. Browning et al.   JOURNAL OF LIPID RESEARCH

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammation stimulates the expression of PCSK9

(2008) Kenneth R. Feingold et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS